"Coagulants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that cause clotting.
Descriptor ID |
D003029
|
MeSH Number(s) |
D27.505.954.502.270
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Coagulants".
Below are MeSH descriptors whose meaning is more specific than "Coagulants".
This graph shows the total number of publications written about "Coagulants" by people in this website by year, and whether "Coagulants" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2012 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2015 | 2 | 0 | 2 |
2016 | 2 | 0 | 2 |
2018 | 1 | 1 | 2 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Coagulants" by people in Profiles.
-
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Jul; 22(7):1880-1893.
-
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. BioDrugs. 2018 Dec; 32(6):561-570.
-
Haemophilia clinical care and research needs: Assessing priorities. Haemophilia. 2018 07; 24(4):e270-e273.
-
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost. 2017 02 28; 117(3):508-518.
-
Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. Haemophilia. 2016 Jul; 22(4):e259-66.
-
Procoagulant snake venoms have differential effects in animal plasmas: Implications for antivenom testing in animal models. Thromb Res. 2016 Jan; 137:174-177.
-
Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015 Jun; 13(6):967-77.
-
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014 Nov; 12(11):1788-800.
-
Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost. 2012 May; 10(5):773-80.